• Conference Proceeding

Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip Or knee arthroplasty that have moderate impairment of renal function

Citation

Wolowacz, S., Roskell, N., Plumb, J., Clemens, A., Robinson, P., Dolan, G., & Brenkel, I. (2009). Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip Or knee arthroplasty that have moderate impairment of renal function. In [12], pp. A151–A151. .

Abstract